Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC) Clear all
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ABBV-969
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 5:35 PM EDT
Temporarily Not Available No phase listed Expanded access
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer
Interventions
[Lu-177]-PNT2002
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
U.S. locations
7
States / cities
Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tinengotinib, abiraterone acetate with prednisone, Enzalutamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Campbell, California • Duarte, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (GnRH) antagonists
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vismodegib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Cancer AJCC v8
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Male only
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
29
States / cities
Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fractionated dose of 225Ac-J591, 68Ga-PSMA-HBED-CC injection, Multiple single doses of 225Ac-J591
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, EPI-7386 with Enzalutamide
Drug
Lead sponsor
ESSA Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Tucson, Arizona • Port Saint Lucie, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA ADC
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
36
States / cities
Birmingham, Alabama • Tucson, Arizona • Burbank, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
GSK5458514
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
mCRPC
Interventions
Talazoparib with enzalutamide, Placebo with enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
131
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
Interventions
BKM120
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
BAY2315497 Injection, Darolutamide(BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New Orleans, Louisiana • Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
AAA617, 68Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 5:35 PM EDT